Propanc Biopharma, Inc. SEC Filings

Propanc Biopharma, Inc. is registering up to 2,500,000 shares of Common Stock for resale by Hexstone Capital LLC. These shares are issuable upon conversion of up to 9,900 shares of Series C Preferred Stock that may be acquired through a warrant.

Propanc already received $1,000,000 in gross proceeds from issuing 100 Series C Preferred shares and the warrant, and would receive up to $99,000,000 more if the warrant is fully exercised for cash. The company will not receive proceeds from selling stockholder resales. The Series C converts at the lesser of $125.00 or 85% of a volume-based market price, floored at $12.50, subject to a 4.99% (or 9.99% on notice) beneficial ownership cap and a 9,500,000-share reserve.

Shares outstanding were 3,503,116 as of July 6, 2026, or 6,003,116 if all registered shares are issued. Propanc reports no revenue, a nine‑month net loss of $15,221,714, an accumulated deficit of $140,843,234, cash of $443,702, and substantial doubt about its ability to continue as a going concern.

Propanc Biopharma, Inc. reported that effective July 8, 2026, Annie Van Broekhoven retired and stepped down from its Board of Directors, and the company accepted her resignation. The Board simultaneously filled the resulting vacancy.

The Board appointed Carlo Campiciano to serve as a director until his resignation or removal. Campiciano is a qualified accountant and member of the Institute of Public Accountants in Australia, with a Master of Entrepreneurship and Innovation and US GAAP certification. He previously served as CFO and Company Secretary of ASX-listed MedAdvisor Limited, where he helped raise multiple rounds of capital and supported the company’s ASX listing and international expansion. The company and Campiciano entered into a Director Agreement dated July 8, 2026, included as an exhibit.

Propanc Biopharma reported no revenue for the quarter ended March 31, 2026 and remains a development‑stage oncology company focused on its preclinical PRP pro‑enzyme candidate. The company posted a quarterly net loss of $6.36 million and a nine‑month net loss of $14.29 million, driven largely by stock‑based administrative expenses.

Cash increased to $443,702 at March 31, 2026 from $12,088 at June 30, 2025, supported by financing inflows including a common stock offering and issuance of Series C Preferred Stock and related warrants. Total assets were $14.33 million, mostly prepaid equity‑settled service costs, while total liabilities were $3.51 million and stockholders’ equity was $9.83 million.

Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, negative operating cash flow of $4.08 million over nine months, and a cumulative deficit of $140.84 million. As of May 14, 2026 there were 56,959,280 common shares outstanding, reflecting significant recent equity issuance and conversions.

Propanc Biopharma, Inc. has filed a resale registration statement covering up to 15,000,000 shares of common stock for a single selling stockholder, Hexstone Capital LLC. These shares are issuable upon conversion of Series C Preferred Stock already issued or issuable under a warrant.

The company will not receive proceeds from any resale of these shares, only from potential future cash exercises of the warrant. Propanc is a development‑stage oncology company focused on its lead candidate PRP for pancreatic, ovarian and colorectal cancers, with no revenue, large accumulated losses, and substantial doubt about its ability to continue as a going concern absent new capital.

Propanc Biopharma, Inc. approved the issuance of specific restricted common shares to officers, directors and service providers and authorized a reverse stock split between 1-for-10 and 1-for-30.

The Board approved detailed New Stock Issuances on March 16, 2026, including 7,000,000 shares to James Nathanielsz and multiple grants of 2,000,000–2,500,000 shares to named recipients. The Board also approved a Reverse Stock Split in a ratio between 1:10 and 1:30. As of March 16, 2026, there were 20,900,649 shares of Common Stock outstanding; the Majority Stockholder (holding 8,732 common shares and 1 Series B Preferred share) voted in favor, representing approximately 50.01% of voting power.

Propanc Biopharma, Inc. notifies shareholders that its Board and the holder of a majority of voting power approved two corporate actions by written consent: (1) the issuance of restricted Common Stock to officers, directors and service providers and (2) a reverse stock split at a ratio between 1:10 and 1:30.

The Information Statement lists specific New Stock Issuances totaling 33,000,000 shares (7,000,000 to James Nathanielsz and multiple allocations of 2,000,000 and 2,500,000 shares to others) and states there were 20,900,649 shares outstanding as of March 16, 2026. The Majority Stockholder (holding 8,732 common shares and 1 share of Series B Preferred) voted in favor, representing approximately 50.01% of the voting equity.

Propanc Biopharma, Inc. notifies shareholders that its Board and a majority stockholder approved two corporate actions by written consent on March 16, 2026: (1) issuance of a total of 33,000,000 restricted shares to officers, directors and service providers (the "New Stock Issuances"); and (2) a reverse stock split at a ratio between 1:10 and 1:30 (the "Reverse Stock Split").

The Information Statement states there were 20,900,649 shares outstanding as of March 16, 2026, and the Majority Stockholder holding 8,732 common shares plus 1 share of Series B Preferred (approximately 50.01% of voting power) consented. The Reverse Stock Split, when processed and approved by Nasdaq, would reduce outstanding shares to between approximately 2,090,065 and 696,688, with proportional adjustments to option and warrant terms.

Propanc Biopharma, Inc. registers up to 7,000,000 shares of Common Stock for resale by the selling stockholder.

The prospectus states the registered shares include conversions of 100 Initial Shares of Series C Preferred Stock and 9,900 Series C Preferred Stock issuable upon exercise of a Warrant held by Hexstone Capital LLC, and that the Company will not receive proceeds from resales by the selling stockholder. The Warrant exercise price is stated as $10,000 per Series C share; if exercised in full for cash, the Company would receive approximately $99,000,000. The Certificate of Designation includes a 4.99% beneficial ownership limitation (adjustable to 9.99% with notice). Shares outstanding are reported as 15,091,133 before and 22,091,133 after the offering, assuming sale of all registered Shares.